4.4 Review

Targeting the 5-HT2C Receptor in Biological Context and the Current State of 5-HT2C Receptor Ligand Development

期刊

CURRENT TOPICS IN MEDICINAL CHEMISTRY
卷 19, 期 16, 页码 1381-1398

出版社

BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1568026619666190709101449

关键词

5-HT2C receptor; Agonists; Allosteric modulation; Positive allosteric modulators; Target selectivity; Signaling bias; Drug discovery; Ligand development; Pharmacological probes; Central nervous system disorders; Neurotherapeutics

资金

  1. National Institute on Drug Abuse [R01 DA038446, T32 DA07287, F31 DA045511]
  2. Ruth L. Kirschstein National Research Service Award of the National Institutes of Health

向作者/读者索取更多资源

Serotonin (5-HT) 5-HT2C receptor (5-HT2CR) is recognized as a critical mediator of disease-related pathways and behaviors based upon actions in the central nervous system (CNS). Since 5-HT2CR is a class A G protein-coupled receptor (GPCR), drug discovery efforts have traditionally pursued the activation of the receptor through synthetic ligands with agonists proposed for the treatment of obesity, substance use disorders and impulse control disorders while antagonists may add value for the treatment of anxiety, depression and schizophrenia. The most significant agonist discovery to date is the FDA-approved anti-obesity medication lorcaserin. In recent years, efforts towards developing other mechanisms to enhance receptor function have resulted in the discovery of Positive Allosteric Modulators (PAMs) for the 5-HT2C, with several molecule series now reported. The biological significance and context for signaling and function of the 5-HT2CR, and the current status of 5-HT2CR agonists and PAMs are discussed in this review.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据